Immunology Investor Event
SAR441566: The first oral TNFα inhibitor
Tackling the largest therapeutic class in immunology
Antibody-like efficacy in arthritis model
60
sanofi
membrane
TNFa
W
soluble
TNFα
Arthritis score
Antibody-like efficacy
seen at 10mg/kg
69%
71%
85%
***
50
15%
40
30
20
10
0 Vehicle
1
3
10
30
Anti-TNF
mAb
SAR441566 mg/kg
SAR441566 distorts
soluble TNFα trimer
conformation and disrupts
TNFR1 signaling
Listeria infection model
Y
TNFR2
TNFR1
- Tissue repair
- Protection from infection
- Treg expansion
- Pro-inflammatory
cytokines and cell death.
% Survival
100
80
60
Vehicle
40
SAR TNFI 30 mg/kg
▾ Anti-TNF mAb
20
0 0
4
6
8
10
12
14
Day Post Infection
SAR441566, small molecule
TNFα inhibitor, offers potential
for antibody-like efficacy with
oral convenience
Selective inhibition of TNFR1
signaling offers potential for
lower infection risk and
improved efficacy
Unique Mechanism of Action
presents a potential to
differentiate from marketed
TNFα biologics and JAK
inhibitors
Oral TNFα inhibitor treated mice do not succumb to listeria
infection in contrast to anti-TNF biologic
49 Immunology Investor Event
Phase 1 in healthy subjects ongoing
Proof of Mechanism readout in Psoriasis early 2023View entire presentation